{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T20:34:20Z","timestamp":1794170060418,"version":"4.8.0"},"reference-count":20,"publisher":"American Association for Cancer Research (AACR)","issue":"5","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Purpose: Ovarian cancer is the leading cause of death from gynecologic malignancy in the United States, with high rates of recurrence and eventual resistance to cytotoxic chemotherapy. Model systems that allow for accurate and reproducible target discovery and validation are needed to support further drug development in this disease.<\/jats:p>\n                  <jats:p>Experimental Design: Clinically annotated patient-derived xenograft (PDX) models were generated from tumor cells isolated from the ascites or pleural fluid of patients undergoing clinical procedures. Models were characterized by IHC and by molecular analyses. Each PDX was luciferized to allow for reproducible in vivo assessment of intraperitoneal tumor burden by bioluminescence imaging (BLI). Plasma assays for CA125 and human LINE-1 were developed as secondary tests of in vivo disease burden.<\/jats:p>\n                  <jats:p>Results: Fourteen clinically annotated and molecularly characterized luciferized ovarian PDX models were generated. Luciferized PDX models retain fidelity to both the nonluciferized PDX and the original patient tumor, as demonstrated by IHC, array CGH, and targeted and whole-exome sequencing analyses. Models demonstrated diversity in specific genetic alterations and activation of PI3K signaling pathway members. Response of luciferized PDX models to standard-of-care therapy could be reproducibly monitored by BLI or plasma markers.<\/jats:p>\n                  <jats:p>Conclusions: We describe the establishment of a collection of 14 clinically annotated and molecularly characterized luciferized ovarian PDX models in which orthotopic tumor burden in the intraperitoneal space can be followed by standard and reproducible methods. This collection is well suited as a platform for proof-of-concept efficacy and biomarker studies and for validation of novel therapeutic strategies in ovarian cancer. Clin Cancer Res; 23(5); 1263\u201373. \u00a92016 AACR.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-16-1237","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T22:33:26Z","timestamp":1472510006000},"page":"1263-1273","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics"],"prefix":"10.1158","volume":"23","author":[{"given":"Joyce F.","family":"Liu","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeetha","family":"Palakurthi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zeng","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zhou","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ivanova","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis K.","family":"Zervantonakis","sequence":"additional","affiliation":[{"name":"3Department of Cell Biology, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Selfors","sequence":"additional","affiliation":[{"name":"3Department of Cell Biology, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Shen","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Children's Hospital Boston, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin C.","family":"Pritchard","sequence":"additional","affiliation":[{"name":"5Department of Laboratory Medicine, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zheng","sequence":"additional","affiliation":[{"name":"6Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilmos","family":"Adleff","sequence":"additional","affiliation":[{"name":"7The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eniko","family":"Papp","sequence":"additional","affiliation":[{"name":"7The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Piao","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Novak","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Fotheringham","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerburg M.","family":"Wulf","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"English","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Kirschmeier","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor E.","family":"Velculescu","sequence":"additional","affiliation":[{"name":"7The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cloud","family":"Paweletz","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon B.","family":"Mills","sequence":"additional","affiliation":[{"name":"9Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Livingston","sequence":"additional","affiliation":[{"name":"10Department of Genetics, Harvard Medical School, Boston, Massachusetts."},{"name":"11Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan S.","family":"Brugge","sequence":"additional","affiliation":[{"name":"3Department of Cell Biology, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Drapkin","sequence":"additional","affiliation":[{"name":"12Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2017,2,28]]},"reference":[{"key":"2022061102431879300_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2022061102431879300_bib2","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat Commun"},{"key":"2022061102431879300_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ygyno.2015.08.017","article-title":"Beyond genomics: critical evaluation of cell line utility for ovarian cancer research","volume":"139","author":"Elias","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2022061102431879300_bib4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ygyno.2015.05.040","article-title":"In vivo tumor growth of high-grade serous ovarian cancer cell lines","volume":"138","author":"Mitra","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2022061102431879300_bib5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov"},{"key":"2022061102431879300_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","article-title":"Patient-derived tumour xenografts as models for oncology drug development","volume":"9","author":"Tentler","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061102431879300_bib7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.molonc.2014.01.008","article-title":"Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts","volume":"8","author":"Topp","year":"2014","journal-title":"Mol Oncol"},{"key":"2022061102431879300_bib8","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1158\/1078-0432.CCR-13-2611","article-title":"Tumorgrafts as in vivo surrogates for women with ovarian cancer","volume":"20","author":"Weroha","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022061102431879300_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.tranon.2015.03.004","article-title":"[(18F)]-Fluorodeoxyglucose positron emission tomography\/computed tomography of LAPC4-CR castration-resistant prostate cancer xenograft model in soft tissue Compartments","volume":"8","author":"McCall","year":"2015","journal-title":"Transl Oncol"},{"key":"2022061102431879300_bib10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nature05329","article-title":"Global variation in copy number in the human genome","volume":"444","author":"Redon","year":"2006","journal-title":"Nature"},{"key":"2022061102431879300_bib11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"2022061102431879300_bib12","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061102431879300_bib13","doi-asserted-by":"crossref","first-page":"12629","DOI":"10.1073\/pnas.1007983107","article-title":"Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing","volume":"107","author":"Walsh","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061102431879300_bib14","doi-asserted-by":"crossref","first-page":"283ra53","DOI":"10.1126\/scitranslmed.aaa7161","article-title":"Personalized genomic analyses for cancer mutation discovery and interpretation","volume":"7","author":"Jones","year":"2015","journal-title":"Sci Translat Med"},{"key":"2022061102431879300_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nature14969","article-title":"The genomic landscape of response to EGFR blockade in colorectal cancer","volume":"526","author":"Bertotti","year":"2015","journal-title":"Nature"},{"key":"2022061102431879300_bib16","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/1535-7163.MCT-06-0334","article-title":"Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells","volume":"5","author":"Tibes","year":"2006","journal-title":"Mol Cancer Therap"},{"key":"2022061102431879300_bib17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0092-8674(03)00401-X","article-title":"Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence","volume":"113","author":"Narita","year":"2003","journal-title":"Cell"},{"key":"2022061102431879300_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1535-6108(03)00003-5","article-title":"Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification","volume":"3","author":"Armstrong","year":"2003","journal-title":"Cancer Cell"},{"key":"2022061102431879300_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ab.2010.11.012","article-title":"Analysis of two pharmacodynamic biomarkers using acoustic micro magnetic particles on the ViBE bioanalyzer","volume":"410","author":"Yan","year":"2011","journal-title":"Analyt Biochem"},{"key":"2022061102431879300_bib20","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.1158\/0008-5472.CAN-07-0605","article-title":"Serial assessment of human tumor burdens in mice by the analysis of circulating DNA","volume":"67","author":"Rago","year":"2007","journal-title":"Cancer Res"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/23\/5\/1263\/1931351\/1263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/23\/5\/1263\/1931351\/1263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T11:46:32Z","timestamp":1654947992000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/23\/5\/1263\/122865\/Establishment-of-Patient-Derived-Tumor-Xenograft"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,28]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,2,28]]},"published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-1237","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1078-0432.22466688.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22466694.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22466691.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22466691","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22466685.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22466694","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22466685","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22466688","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.c.6526395.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6526395","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.3410\/f.726696639.793527295","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,28]]}}}